CG
LGND icon

Cutler Group’s Ligand Pharmaceuticals LGND Stock Holding History

Cutler Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,771
Closed -$102K – 5197
2020
Q3 		$102K Hold
5,771
– – 0.01% 1314
2020
Q2 		$88K Buy
+5,771
New +$366K 0.01% 1385
2020
Q1 		– Sell
-7,855
Closed -$42K – 4389
2019
Q4 		$42K Sell
7,855
-160
-2% -$10.7K ﹤0.01% 1740
2019
Q3 		$96K Buy
+8,015
New +$503K 0.01% 1090
2017
Q2 		– Sell
-19,396
Closed -$30K – 6732
2017
Q1 		$30K Sell
19,396
-99,226
-84% -$6.53M ﹤0.01% 2903
2016
Q4 		$330K Buy
118,622
+104,676
+751% +$6.61M 0.01% 950
2016
Q3 		$132K Buy
13,946
+6,732
+93% +$494K 0.01% 1578
2016
Q2 		$13K Sell
7,214
-62,517
-90% -$4.64M ﹤0.01% 3843
2016
Q1 		$114K Buy
+69,731
New +$4.24M 0.01% 1489

Other funds holding LGND

William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Cutler Group's LGND Position: Q1 2020 in Review

Cutler Group sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 2,725 shares — an estimated $177K sold.

Cutler Group first reported a position in LGND in Q4 2015 and held it in 9 quarters. The position peaked at $1.59M in Q4 2016. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Cutler Group reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Cutler Group sold 2,725 Ligand Pharmaceuticals shares in Q1 2020, an estimated $177K.
  • Cutler Group first reported a position in Ligand Pharmaceuticals in Q4 2015 and held it in 9 quarters.
  • Cutler Group's Ligand Pharmaceuticals position peaked at $1.59M in Q4 2016.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Cutler Group's 13F filing for Q1 2020, filed 7 May 2020.